Head and Neck Cancer

PV QA 2 - Poster Viewing Q&A 2

MO_29_2697 - Randomized Double-blind, Placebo-Controlled Phase III trial Evaluating the Effect of Oral glutamine on Radiation-induced Oral Mucositis and Neck Dermatitis in Head and Neck Cancer Patients

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

Randomized Double-blind, Placebo-Controlled Phase III trial Evaluating the Effect of Oral glutamine on Radiation-induced Oral Mucositis and Neck Dermatitis in Head and Neck Cancer Patients
H. H. Lee1, C. J. Huang1, M. Y. Huang1, F. Chen1, Y. T. Wang1, C. H. Chen1, S. S. Yuan1, C. M. Huang2, P. T. Fang1, K. H. Luo1, H. Y. Chuang1, and Y. Y. Wang1; 1Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, 2Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

Purpose/Objective(s): Whether oral glutamine help alleviate radiotherapy (RT)–induced toxicity remains controversial. We aim to explore the association between oral glutamine and acute toxicities in patients with head and neck cancer under RT.

Materials/Methods: This is a parallel, double-blind, randomized, placebo-controlled phase III trial conducted in one university hospital. A central randomization center used computer generated tables to allocate intervention for 71 patients with stage I-IV head and neck cancer. We excluded patients with diabetes mellitus, renal or hepatic insufficiency, history of prior irradiation or sepsis, distant metastasis, or with Eastern Cooperative Oncology Group (ECOG) performance status scoring larger than 2. The oral mucosa and the neck skin at baseline were healthy in all patients. The patients, care providers, and investigators were blinded to group assignment. Eligible patients received either oral glutamine (5g glutamine and 10g maltodextrin) or placebo (15g maltodextrin) 3 times daily during the period: 7 days before RT to 14 days after RT. The primary and secondary endpoints were radiation-induced oral mucositis and neck dermatitis, respectively. They were documented in agreement with the National Cancer Institute Common Terminology Criteria for Adverse Events version 3. Cox regression, log-rank test, and Kaplan–Meier curves were calculated.

Results: Seventy-one patients were randomized. We included 64 patients (placebo n=33; glutamine n=31) who completed RT for intention-to-treat (ITT) analysis. Five patients were excluded because of non-adherence, leaving 59 (placebo n=29; glutamine n=30) patients for per-protocol (PP) analysis. The use of glutamine, higher mean dose to the oral cavity, the incidence of opioid use and the decrease of body mass index (BMI) were significantly related to severe mucositis in the univariate ITT analysis. In multivariate analysis, glutamine had no significant effect on the severity of oral mucositis (OR 0.3, 95% CI 0.05-1.67; P =0.169). Only BMI change was significant in both multivariate ITT (OR 0.41, 95% CI 0.20-0.84; P =0.015) and PP analysis (OR 0.40, 95% CI 0.20-0.83; P =0.014) after adjusting baseline nutritional status and biochemical profile, primary tumor location and stage, severity of neck dermatitis, mean and maximum dose to the oral cavity, RT interruption days, PNI change during RT, performance status, operation, chemotherapy, alcohol or tobacco use history, betel nut chewing habits, the incidence of opioid use etc. No difference was found in the incidence and the severity of neck dermatitis between the 2 arms.

Conclusion: The decrease of BMI during RT was an independent and stable factor for the severity of oral mucositis, but not the use of glutamine.

Author Disclosure: H. Lee: None. C. Huang: None. F. Chen: None. H. Chuang: None.

Hsin-Hua Lee, MD

Biography:
Hsin-Hua Lee is a radiation oncologist in Kaohsiung Medical University Hospital. Kaohsiung Medical University provides a broad portfolio of reactive and proactive teaching encompassing all elements of medicine. Dr. Lee brings to her position a well-established background in medical research and education. She is now in the Doctoral Degree Program in Environmental and Occupational Medicine which was founded in Division of Environmental Health & Occupational Medicine, National Health Research Institutes, and Kaohsiung Medical University in 2010.
The National Health Research Institutes (NHRI) is a non-profit foundation established in 1995.
Dr.Lee specializes in treatment for breast cancer, head and neck cancer, prostate cancer, colorectal cancer, and thoracic oncology with a focus on lung cancer. She completed her residency in radiation oncologist at the Kaohsiung Medical University Hospital. She earned her Doctor of Medicine at China Medical University, located in Taichung, central Taiwan. When not at work, she is active in traveling and learning new languages. She's fluent in English, Mandarin, Taiwanese, and is working on Japanese, Spanish and French on a daily basis. She also focuses on early exposure of reading to her young children.

Presentation(s):

Send Email for Hsin-Hua Lee


Assets

MO_29_2697 - Randomized Double-blind, Placebo-Controlled Phase III trial Evaluating the Effect of Oral glutamine on Radiation-induced Oral Mucositis and Neck Dermatitis in Head and Neck Cancer Patients



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Randomized Double-blind, Placebo-Controlled Phase III trial Evaluating the Effect of Oral glutamine on Radiation-induced Oral Mucositis and Neck Dermatitis in Head and Neck Cancer Patients